NSE filing, NSE: PAR. Summary written from the filing by ALFA Finder's alert engine.
Par Drugs & Chemicals Ltd: key numbers
- Share price
- ₹114.96
- Market cap
- ₹141.4 Cr
- Revenue (annual)
- ₹103.7 Cr
- Net profit (annual)
- ₹13.11 Cr
- P/E (TTM)
- 9.8×Sector 46.1×
- Promoter holding
- 73.41%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Par Drugs & Chemicals Ltd
All →Par Drugs & Chemicals Board Meeting Date
Par Drugs and Chemicals Limited will hold a board meeting on October 29, 2026, to consider and approve its half-yearly unaudited financial results.
Par Drugs & Chemicals Other Announcement
The company submitted the routine Regulation 74(5) compliance certificate from its RTA regarding share dematerialization for the quarter ended September 30, 2026.
Par Drugs & Chemicals Management Change
Par Drugs re-appointed its statutory auditor and executive director/CEO. These appointments were approved at the company's 27th Annual General Meeting.
Par Drugs & Chemicals Annual General Meeting
Par Drugs and Chemicals Limited held its 27th Annual General Meeting on September 26, 2026. Management reviewed the company's financial performance and business affairs during the session.
Par Drugs & Chemicals Management Change
Par Drugs and Chemicals Limited has re-appointed M/s. Siddhpura & Co. as Internal Auditor and M/s. Maulin Shah & Associates as Cost Auditor.
Par Drugs & Chemicals Annual General Meeting
Par Drugs and Chemicals Limited has scheduled its 27th Annual General Meeting for September 26, 2026, in Vadodara to transact scheduled ordinary and special business.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.